Drug details

Synjardy XR Extended-release Tablets (empagliflozin and metformin hydrochloride extended-release)

type of Antidiabetics, SGLT2 Inhibitors, Antidiabetics, Biguanides

Synjardy XR (empagliflozin and metformin hydrochloride extended-release) tablets, for oral use is a combination of a sodium-glucose co-transporter 2 (SGLT2) inhibitor and a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both empagliflozin and metformin is appropriate.

This drug may have the following side effects:
  • hives,
  • difficulty breathing,
  • swelling of your face, lips, tongue, or throat,
  • nausea,
  • vomiting,
  • fever,
  • lightheadedness,
  • confusion,
  • tiredness,
  • stomach pain,
  • dizziness,
  • weakness,
  • little or no urination,
  • increased urination,
  • trouble breathing,
  • feeling cold,
  • unusual drowsiness,
  • feeling unwell,
  • unusual muscle pain,
  • irregular heart rate,
  • blood in your urine, and
  • pain in your pelvis or back
  • pain or burning when you urination,
The following drugs are related to Synjardy XR Extended-release Tablets, either as a replacement or used together:
  • Actos (pioglitazone hydrochloride)
  • Byetta (exenatide injection)
  • Invokana (canagliflozin tablets)
  • Diabinese (chlorpropamide)
  • Zegalogue (dasiglucagon injection)
  • Trijardy XR (empagliflozin, linagliptin, and metformin hydrochloride extended-release tablets)
  • Glucotrol (glipizide)
  • Glucotrol XL (glipizide extended release)
  • Glyset (miglitol)
  • NovoLog (insulin aspart [rdna origin] inj)
  • Lantus (insulin glargine [rdna origin] injection)
  • Semglee (insulin glargine injection)
  • Lyumjev (insulin lispro-aabc injection)
  • Janumet (sitagliptin metformin hcl)
  • Janumet XR (sitagliptin and metformin hcl)
  • Symlin (pramlintide acetate injection)